{
    "clinical_study": {
        "@rank": "99173", 
        "arm_group": [
            {
                "arm_group_label": "HCV genotype GT3 participants (Panel A)", 
                "arm_group_type": "Experimental", 
                "description": "MK-8876 200 mg oral once daily (qd) for 7 days"
            }, 
            {
                "arm_group_label": "HCV genotype GT3 participants (Panel B)", 
                "arm_group_type": "Experimental", 
                "description": "MK-8876 \u2264800 mg oral qd for 7 days"
            }, 
            {
                "arm_group_label": "HCV genotype GT3 participants (Panel C)", 
                "arm_group_type": "Experimental", 
                "description": "MK-8876 \u2264800 mg oral qd for 7 days"
            }, 
            {
                "arm_group_label": "HCV genotype GT3 participants (Panel D)", 
                "arm_group_type": "Experimental", 
                "description": "MK-8876 \u2264800 mg oral qd for 7 days"
            }, 
            {
                "arm_group_label": "HCV genotype GT1a participants (Panel E)", 
                "arm_group_type": "Experimental", 
                "description": "MK-8876 \u2264800 mg oral qd for 7 days"
            }, 
            {
                "arm_group_label": "HCV genotype GT1a participants (Panel F)", 
                "arm_group_type": "Experimental", 
                "description": "MK-8876 \u2264800 mg oral qd for 7 days"
            }, 
            {
                "arm_group_label": "HCV genotype GT1b participants (Panel G)", 
                "arm_group_type": "Experimental", 
                "description": "MK-8876 \u2264800 mg oral qd for 7 days"
            }, 
            {
                "arm_group_label": "HCV genotype GT1b participants (Panel H)", 
                "arm_group_type": "Experimental", 
                "description": "MK-8876 \u2264800 mg oral qd for 7 days"
            }, 
            {
                "arm_group_label": "HCV genotype GT2 participants (Panel I)", 
                "arm_group_type": "Experimental", 
                "description": "MK-8876 \u2264800 mg oral qd for 7 days"
            }, 
            {
                "arm_group_label": "HCV genotype GT2 participants (Panel J)", 
                "arm_group_type": "Experimental", 
                "description": "MK-8876 \u2264800 mg oral qd for 7 days"
            }
        ], 
        "brief_summary": {
            "textblock": "This adaptive design study will evaluate the safety, pharmacokinetics, and effect on\n      hepatitis C virus (HCV) RNA levels of multiple doses of MK-8876 in participants with HCV\n      infection. The study will consist of 4 parts evaluating participants infected with specific\n      hepatitis C virus genotypes and up to 10 panels allowing for additional participants to\n      enroll in each panel as specified in the study analysis. The hypothesis evaluated in the\n      study is that a \u22652.5 log IU/mL reduction in HCV RNA from Baseline will accompany multiple\n      dose administration of MK-8876 in participants with HCV infection."
        }, 
        "brief_title": "Safety, Pharmacokinetics, and Pharmacodynamics of MK-8876 in Participants With Hepatitis C Infection (MK-8876-003)", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "condition": "HCV Infection", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male, or female of non-childbearing potential. Non-childbearing potential is defined\n             as postmenopausal without menses for \u22651 year or after medically documented\n             hysterectomy, oophorectomy, or tubal ligation\n\n          -  Participants with female partner of childbearing potential must use a medically\n             acceptable method of contraception through 90 days after the last dose of study drug\n\n          -  Males should use a condom and their partner of childbearing potential must use\n             hormonal contraception, intrauterine device, diaphragm, cervical cap, or female\n             condom\n\n          -  Body mass index between 18 and 37 kg/m^2\n\n          -  Clinical diagnosis of chronic HCV infection defined by positive serology for HCV for\n             \u22656 months\n\n          -  Agrees to follow the smoking and other trial restrictions\n\n        Exclusion Criteria:\n\n          -  Mentally or legally institutionalized or incapacitated, has significant emotional\n             problems at study start or has clinically significant psychiatric disorder of the\n             last 5 years\n\n          -  History of clinically significant endocrine, gastrointestinal (except HCV infection),\n             cardiovascular, hematological, hepatic, immunological, renal, respiratory, or\n             genitourinary abnormalities or diseases\n\n          -  History of stroke, chronic seizures, or major neurological disorder\n\n          -  History of cancer (except adequately treated non-melanomatous skin carcinoma,\n             carcinoma in situ of the cervix, or other malignancies which have been successfully\n             treated for \u226510 years\n\n          -  History of significant multiple and/or severe allergies or has had an anaphylactic\n             reaction or significant intolerability to drugs or food\n\n          -  History of clinically significant hepatic disease, Gilbert's disease, biliary tract\n             disease, or human immunodeficiency virus\n\n          -  Had major surgery or donated or lost >1 unit of blood within 4 weeks before the study\n\n          -  Participated in another investigational trial within 4 weeks before the study\n\n          -  Is unable to refrain from or anticipates the use of any medication from 2 weeks\n             before the study and throughout the study\n\n          -  Consumes >2 glasses of alcoholic beverages per day\n\n          -  Consumes >6 servings (1 serving is ~120 mg caffeine) of coffee, tea, cola, energy\n             drinks, or other caffeinated beverages per day\n\n          -  Regular user of any illicit drugs or history of drug abuse within 12 months of the\n             study\n\n          -  Evidence or history of chronic hepatitis not caused by HCV (except acute\n             non-HCV-related hepatitis that resolved >6 months before the study)\n\n          -  Previous treatment with another HCV non-nucleoside inhibitor (previous use of other\n             HCV investigational therapies or marketed compounds is permitted if treatment ended\n             \u22653 months before the study)\n\n          -  Clinical or laboratory evidence of advanced or decompensated liver disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "9", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01930058", 
            "org_study_id": "8876-003", 
            "secondary_id": "2013-002566-39"
        }, 
        "intervention": {
            "arm_group_label": [
                "HCV genotype GT3 participants (Panel A)", 
                "HCV genotype GT3 participants (Panel B)", 
                "HCV genotype GT3 participants (Panel C)", 
                "HCV genotype GT3 participants (Panel D)", 
                "HCV genotype GT1a participants (Panel E)", 
                "HCV genotype GT1a participants (Panel F)", 
                "HCV genotype GT1b participants (Panel G)", 
                "HCV genotype GT1b participants (Panel H)", 
                "HCV genotype GT2 participants (Panel I)", 
                "HCV genotype GT2 participants (Panel J)"
            ], 
            "intervention_name": "MK-8876 200 mg or \u2264800 mg", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 27, 2014", 
        "number_of_arms": "10", 
        "official_title": "A Multiple Dose Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MK-8876 in Hepatitis C Patients", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Moldova: Health Ministry of Republic of Moldova", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Mean maximum change from baseline in HCV RNA", 
            "safety_issue": "No", 
            "time_frame": "Baseline and up to Day 7"
        }, 
        "removed_countries": {
            "country": [
                "Germany", 
                "Moldova, Republic of"
            ]
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01930058"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Steady state mean area under the MK-8876 plasma concentration versus time curve (AUC0-24 hr)", 
                "safety_issue": "No", 
                "time_frame": "Before and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours after dosing on Day 7"
            }, 
            {
                "measure": "Steady state mean MK-8876 plasma concentration (C24 hr)", 
                "safety_issue": "No", 
                "time_frame": "24 hours after dosing on Day 7"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}